跳至主要内容
临床试验/NCT02235415
NCT02235415已完成不适用

Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension, Under Normal Conditions Compared With an Open Clinical Trial

Boehringer Ingelheim0 个研究点目标入组 24,526 人开始时间: 1998年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
24,526
主要终点
Assessment of efficacy by the investigator on a 4-point verbal rating scale based on changes in blood pressure

研究概览

简要总结

Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Non-hospitalised patients of both sexes aged 18 years or more with essential hypertension requiring treatment according to the recommendations of the German League for Hypertension

排除标准

  • Patients who had the contraindications listed in the product information (the case report file contained a copy of the product information)

研究组 & 干预措施

Motens

干预措施: Motens® (lacidipine) (Drug)

结局指标

主要结局

Assessment of efficacy by the investigator on a 4-point verbal rating scale based on changes in blood pressure

时间窗: Up to 12 weeks after start of drug administration

Number of patients with adverse events

时间窗: Up to 12 weeks after start of drug administration

Assessment of tolerability by investigator on a 4-point verbal rating scale

时间窗: Up to 12 weeks after start of drug administration

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Observation of the Efficacy and Tolerance of Motens®... | 临床试验